Working… Menu

Study of KRYSTEXXA® (Pegloticase) Plus Methotrexate in Patients With Uncontrolled Gout (MIRROR RCT)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03994731
Recruitment Status : Recruiting
First Posted : June 21, 2019
Last Update Posted : October 18, 2019
Information provided by (Responsible Party):
Horizon Pharma Rheumatology LLC

Brief Summary:

Approximately 135 participants will be randomized. Study duration will be approximately 86 weeks.

The purpose of this study is to assess the potential for pegloticase with methotrexate (MTX) to increase the response rate seen with pegloticase alone, and to characterize the safety, tolerability and pharmacokinetics (PK) of the concomitant use of pegloticase with MTX, by comparing pegloticase co-administered with MTX to pegloticase co-administered with placebo for MTX in adults with uncontrolled gout.

Condition or disease Intervention/treatment Phase
Gout Biological: Pegloticase with MTX Biological: Pegloticase with placebo for MTX Phase 4

Detailed Description:
This study is a Phase 4, multicenter, randomized, double-blind, placebo-controlled, parallel-group, efficacy and safety study of pegloticase with MTX vs. pegloticase with placebo for MTX in adult participants with uncontrolled gout.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 135 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy and Safety Study of Methotrexate to Increase Response Rates in Patients With Uncontrolled GOut Receiving KRYSTEXXA® (Pegloticase) (MIRROR Randomized Controlled Trial [RCT])
Actual Study Start Date : June 13, 2019
Estimated Primary Completion Date : February 2021
Estimated Study Completion Date : February 2022

Resource links provided by the National Library of Medicine

Genetics Home Reference related topics: Gout
MedlinePlus related topics: Gout

Arm Intervention/treatment
Experimental: Pegloticase with methotrexate (MTX)
Participants will receive MTX (15 mg) (weekly) during the Tolerability Assessment Period and Run-in Period, then pegloticase (every 2 weeks) with MTX (weekly) for 52 weeks
Biological: Pegloticase with MTX
Participants will receive MTX during the Tolerability Assessment Period then MTX during the run-in period then pegloticase with MTX for 52 weeks
Other Name: methotrexate (MTX)

Placebo Comparator: Pegloticase with placebo for methotrexate (MTX)
Participants will receive MTX (15 mg) (weekly) during the Tolerability Assessment Period, placebo for MTX (weekly) in the Run-in Period, then pegloticase (every 2 weeks) with placebo for MTX (weekly) for 52 weeks
Biological: Pegloticase with placebo for MTX
Participants will receive MTX during the Tolerability Assessment Period then placebo for MTX during the run-in period then pegloticase with placebo for MTX for 52 weeks

Primary Outcome Measures :
  1. Proportion of Serum Uric Acid Responders (sUA < 6 mg/dL) during Month 6 [ Time Frame: Month 6 ]
    Serum uric acid (sUA) responders defined as participants achieving and maintaining sUA <6 mg/dL for at least 80% of the time during Month 6 (Weeks 20, 21, 22, 23 and 24)

Secondary Outcome Measures :
  1. Proportion of Serum Uric Acid Responders (sUA < 6 mg/dL) during Month 9 [ Time Frame: Month 9 ]
    Serum uric acid (sUA) responders defined as participants achieving and maintaining sUA <6 mg/dL for at least 80% of the time during Month 9 (Weeks 32, 34 and 36)

  2. Proportion of Serum Uric Acid Responders (sUA < 6 mg/dL) during Month 12 [ Time Frame: Month 12 ]
    Serum uric acid (sUA) responders defined as participants achieving and maintaining sUA <6 mg/dL for at least 80% of the time during Month 12 (Weeks 48, 50 and 52)

  3. Proportion of participants with complete resolution of ≥ 1 tophi at Week 52 [ Time Frame: Week 52 ]
    proportion of participants with complete resolution of ≥ 1 tophi (using digital photography) at Week 52 in subjects with tophi at baseline

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Willing and able to give informed consent.
  2. Willing and able to comply with the prescribed treatment protocol and evaluations for the duration of the study.
  3. Adult men or women ≥18 years of age.
  4. Uncontrolled gout, defined as meeting the following criteria:

    • Hyperuricemia during the screening period defined as sUA ≥7 mg/dL, and;
    • Failure to maintain normalization of sUA with xanthine oxidase inhibitors at the maximum medically appropriate dose, or with a contraindication to xanthine oxidase inhibitor therapy based on medical record review or subject interview, and;
    • Symptoms of gout including at least 1 of the following:

      • Presence of at least one tophus
      • Recurrent flares defined as 2 or more flares in the past 12 months prior to screening
      • Presence of chronic gouty arthritis
  5. Willing to discontinue any oral urate lowering therapy for at least 7 days prior to MTX dosing at Week -6 and remain off when receiving pegloticase infusions.
  6. Women of childbearing potential (including those with an onset of menopause <2 years prior to screening, non-therapy-induced amenorrhea for <12 months prior to screening, or not surgically sterile [absence of ovaries and/or uterus]) must have negative serum/urine pregnancy tests during Screening and Week -6; subjects must agree to use 2 reliable forms of contraception during the study, one of which is recommended to be hormonal, such as an oral contraceptive. Hormonal contraception must be started ≥1 full cycle prior to Week -6 (start of MTX) and continue for 30 days after the last dose of pegloticase, or at least one ovulatory cycle after the last dose of MTX or placebo for MTX (whichever is the longest duration after the last dose of pegloticase or MTX or placebo for MTX). Highly effective contraceptive methods (with a failure rate <1% per year), when used consistently and correctly, include implants, injectables, combined oral contraceptives, some intrauterine devices, sexual abstinence, or vasectomized partner.
  7. Men who are not vasectomized must agree to use appropriate contraception so as to not impregnate a female partner of reproductive potential during the study, beginning with the initiation of MTX at Week -6 and continuing and for at least 3 months after the last dose of MTX or placebo for MTX.
  8. Able to tolerate MTX 15 mg orally for 2 weeks (Week -6 through Week -4) prior to randomization.

Exclusion Criteria:

  1. Weight >160 kg (352 pounds) at Screening.
  2. Any serious acute bacterial infection, unless treated and completely resolved with antibiotics at least 2 weeks prior to the Week -6 Visit.
  3. Severe chronic or recurrent bacterial infections, such as recurrent pneumonia or chronic bronchiectasis.
  4. Current or chronic treatment with systemic immunosuppressive agents such as MTX, azathioprine, or mycophenolate mofetil; prednisone ≥10 mg/day or equivalent dose of other corticosteroid on a chronic basis (3 months or longer) would also meet exclusion criteria.
  5. History of any transplant surgery requiring maintenance immunosuppressive therapy.
  6. Known history of hepatitis B virus surface antigen positivity or hepatitis B DNA positivity.
  7. Known history of hepatitis C virus RNA positivity.
  8. Known history of Human Immunodeficiency Virus (HIV) positivity.
  9. Glucose-6-phosphate dehydrogenase deficiency (tested at the Screening Visit).
  10. Chronic renal impairment defined as estimated glomerular filtration rate (eGFR) <40 mL/min/1.73 m2 or currently on dialysis.
  11. Non-compensated congestive heart failure or hospitalization for congestive heart failure within 3 months of the Screening Visit, uncontrolled arrhythmia, treatment for acute coronary syndrome (myocardial infarction or unstable angina), or uncontrolled blood pressure (>160/100 mmHg) prior to Randomization at Week -4.
  12. Pregnant, planning to become pregnant, breastfeeding, planning to impregnate female partner, or not on an effective form of birth control, as determined by the Investigator.
  13. Prior treatment with pegloticase, another recombinant uricase (rasburicase), or concomitant therapy with a polyethylene glycol-conjugated drug.
  14. Known allergy to pegylated products or history of anaphylactic reaction to a recombinant protein or porcine product.
  15. Contraindication to MTX treatment or MTX treatment considered inappropriate.
  16. Known intolerance to MTX.
  17. Receipt of an investigational drug within 4 weeks or 5 half-lives, whichever is longer, prior to MTX administration at Week -6 or plans to take an investigational drug during the study.
  18. Liver transaminase levels (AST or ALT) > upper limit of normal (ULN) or albumin < the lower limit of normal (LLN) at the Screening Visit).
  19. Chronic liver disease.
  20. White blood cell count < 4,000/ul, hematocrit < 32 percent, or platelet count <75,000/ul.
  21. Currently receiving systemic or radiologic treatment for ongoing cancer.
  22. History of malignancy within 5 years other than non-melanoma skin cancer or in situ carcinoma of cervix.
  23. Diagnosis of osteomyelitis.
  24. Known history of hypoxanthine-guanine phosphoribosyl-transferase deficiency, such as Lesch-Nyhan and Kelley-Seegmiller syndrome.
  25. Unsuitable candidate for the study, based on the opinion of the Investigator (e.g., cognitive impairment), such that participation might create undue risk to the subject or interfere with the subject's ability to comply with the protocol requirements or complete the study.
  26. Alcohol use in excess of 3 alcoholic beverages per week.
  27. A known intolerance to at least one protocol standard gout flare prophylaxis regimen (i.e. colchicine and/or non-steroidal anti inflammatory drugs and/or low dose prednisone ≤10 mg/day).
  28. Current pulmonary fibrosis, bronchiectasis or interstitial pneumonitis. If deemed necessary by the Investigator, a chest X-ray may be performed during Screening.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03994731

Layout table for location contacts
Contact: Colleen Canavan, BS 866-479-6742
Contact: Molly Weiss, BA 866-479-6742

Layout table for location information
United States, Arkansas
Applied Research Center of Arkansas, Inc Recruiting
Little Rock, Arkansas, United States, 72212
Contact: Rhonda Rowton    501-954-7822   
United States, California
Axis Clinical Trials Recruiting
Los Angeles, California, United States, 90036
Contact: Elianet De La Cruz    310-289-8242   
Medvin Clinical Research Recruiting
Tujunga, California, United States, 91042
Contact: Mayra Francisco    213-281-5146   
United States, Colorado
Denver Arthritis Clinic Recruiting
Denver, Colorado, United States, 80230
Contact: Theresa Hernandez    303-394-2828 ext 177   
United States, Florida
Avail Clinical Research Recruiting
DeLand, Florida, United States, 32720
Contact: Jennifer Dittman    386-785-2400   
Prohealth Research Center Recruiting
Doral, Florida, United States, 33166
Contact: Magda Hernandez    305-960-7934   
Napa Research Center Recruiting
Pompano Beach, Florida, United States, 33064
Contact: Magda Hernandez    305-960-7934   
GCP Clinical Research Recruiting
Tampa, Florida, United States, 33609
Contact: Marlene Klingeman    321-315-0780   
United States, Maryland
MD Medical Research Recruiting
Oxon Hill, Maryland, United States, 20745
Contact: Marie Edwards    301-329-2608   
United States, New York
Buffalo Rheumatology and Medicine Recruiting
Orchard Park, New York, United States, 14127
Contact: Angela Dorsheimer    716-675-2500 ext 251   
United States, North Carolina
Shelby Clinical Research, LLC Recruiting
Shelby, North Carolina, United States, 28150
Contact: Pamela Seagle    980-552-9230   
United States, Ohio
Premier Clinical/STAT Research Recruiting
Dayton, Ohio, United States, 45417
Contact: Derek Tipton    937-223-4229   
Paramount Medical Research & Consulting, LLC Recruiting
Middleburg Heights, Ohio, United States, 44130
Contact: Erika Hannigan    440-826-0742   
Premeir Clinical/STAT Research - Springboro Recruiting
Springboro, Ohio, United States, 45066
Contact: Derek Tipton    937-223-4229   
United States, South Carolina
Articularis Healthcare Group Recruiting
Summerville, South Carolina, United States, 29486
Contact: Soua Xiong    843-572-1818   
United States, Tennessee
West Tennessee Research Institute Recruiting
Jackson, Tennessee, United States, 38305
Contact: Sherry Wiggins    731-633-0045   
United States, Texas
Research Consultants - Frostwood Recruiting
Houston, Texas, United States, 77024
Contact: Roxanne McIntosh    713-932-0054   
Research Consultants - Astoria Recruiting
Houston, Texas, United States, 77089
Contact: Arman Hossain    281-944-3620   
Arthritis Clinic of Central Texas Recruiting
San Marcos, Texas, United States, 78666
Contact: Michelle Kelly    512-667-7123 ext 230   
United States, Washington
Western Washington Arthritis Clinic Recruiting
Bothell, Washington, United States, 98021
Contact: Nicole Bruggman    425-248-2635   
United States, Wisconsin
Rheumatic Disease Center Recruiting
Glendale, Wisconsin, United States, 53219
Contact: Lynn Kritter    414-351-4009   
Sponsors and Collaborators
Horizon Pharma Rheumatology LLC
Layout table for investigator information
Study Director: Colleen Canavan, BS Horizon Pharma Rheumatology LLC

Layout table for additonal information
Responsible Party: Horizon Pharma Rheumatology LLC Identifier: NCT03994731     History of Changes
Other Study ID Numbers: HZNP-KRY-202
First Posted: June 21, 2019    Key Record Dates
Last Update Posted: October 18, 2019
Last Verified: October 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Horizon Pharma Rheumatology LLC:
uncontrolled gout
Additional relevant MeSH terms:
Layout table for MeSH terms
Joint Diseases
Musculoskeletal Diseases
Crystal Arthropathies
Rheumatic Diseases
Purine-Pyrimidine Metabolism, Inborn Errors
Metabolism, Inborn Errors
Genetic Diseases, Inborn
Metabolic Diseases
Abortifacient Agents, Nonsteroidal
Abortifacient Agents
Reproductive Control Agents
Physiological Effects of Drugs
Antimetabolites, Antineoplastic
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Dermatologic Agents
Enzyme Inhibitors
Folic Acid Antagonists
Immunosuppressive Agents
Immunologic Factors
Antirheumatic Agents
Nucleic Acid Synthesis Inhibitors